Patanol: profile and news

(BW) Alcon's First Quarter Sales Rise 8.1 Percent, Net Earnings ... Apr 24, 2006
...allergy products rose 23.4 percent as the allergy category grew in the US and because major US wholesalers increased their inventories of Patanol(R) ophthalmic ... - Houston Chronicle,

Other information

Indication
For the treatment of the signs and symptoms of allergic conjunctivitis.

Pharmacology
Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Mechanism Of Action
Olopatadine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.

Drug Category
Anti-allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihistamines; Histamine H1 Antagonists; ATC:S01GX09

Brand Names/Synonyms
Olopatadine; Olopatadine Hydrochloride; Patanol

Dosage Forms
LIQUID

Absorption
Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations.

Interactions
-->Interactions for Olopatadine:

No information provided.

Chemical IUPAC Name
Not Available

Chemical Formula
C21H23NO3

Half Life
3 hours

Drug Type
Approved Drug

# Accession No
APRD00310

CAS Registry Number
113806-05-6